1630453 3011082 3004716 9174366 8386983 8923784 1845846 3020513 1657531 8640467 3010982 6086625 2838070 7510833 3026152 2557917 7748459 9748648 6093249 12626685 2905838 2842508 2137196 2934127 2556712 15047688 2982821 8391697 2538621 3898738 2015039 - Search Results

Year	Number of Results
1984	3
1985	4
1986	12
1987	1
1988	6
1989	11
1990	6
1991	6
1992	6
1993	4
1994	7
1995	4
1996	4
1997	2
1998	5
1999	1
2001	1
2002	1
2003	1
2004	1
2014	1
2015	2
2016	1
2021	1
2023	0

1

The coat protein of the yeast double-stranded RNA virus L-A attaches covalently to the cap structure of eukaryotic mRNA.

Blanc A, Goyer C, Sonenberg N. Blanc A, et al. Mol Cell Biol. 1992 Aug;12(8):3390-8. doi: 10.1128/mcb.12.8.3390-3398.1992. Mol Cell Biol. 1992. PMID: 1630453 Free PMC article.

2

Proliferation dependence of topoisomerase II mediated drug action.

Sullivan DM, Glisson BS, Hodges PK, Smallwood-Kentro S, Ross WE. Sullivan DM, et al. Biochemistry. 1986 Apr 22;25(8):2248-56. doi: 10.1021/bi00356a060. Biochemistry. 1986. PMID: 3011082

3

DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II.

Rowe TC, Chen GL, Hsiang YH, Liu LF. Rowe TC, et al. Cancer Res. 1986 Apr;46(4 Pt 2):2021-6. Cancer Res. 1986. PMID: 3004716

4

Differential poisoning of human and Aspergillus nidulans DNA topoisomerase I by bi- and terbenzimidazoles.

Goldman GH, Yu C, Wu HY, Sanders MM, La Voie EJ, Liu LF. Goldman GH, et al. Biochemistry. 1997 May 27;36(21):6488-94. doi: 10.1021/bi963033t. Biochemistry. 1997. PMID: 9174366

5

The role of topoisomerase II alpha and beta in drug resistance.

Hochhauser D, Harris AL. Hochhauser D, et al. Cancer Treat Rev. 1993 Apr;19(2):181-94. doi: 10.1016/0305-7372(93)90034-o. Cancer Treat Rev. 1993. PMID: 8386983 Review. No abstract available.

6

Feasibility of salvage chemotherapy for refractory or relapsed non-Hodgkin's lymphoma with two topoisomerase II inhibitors, MST-16 and VP-16. MST-16 Study Group.

Kagami Y, Ariyoshi Y, Horiuchi A, Kanamaru A, Kano Y, Naoe T, Oguro M, Ohno R, Sampi K, Shirakawa S, Masaoka T, Furue H. Kagami Y, et al. Int J Hematol. 1996 Oct;64(3-4):221-9. doi: 10.1016/0925-5710(96)00488-4. Int J Hematol. 1996. PMID: 8923784 Clinical Trial.

7

Current status of etoposide in the management of small cell lung cancer.

Johnson DH, Hainsworth JD, Hande KR, Greco FA. Johnson DH, et al. Cancer. 1991 Jan 1;67(1 Suppl):231-44. doi: 10.1002/1097-0142(19910101)67:1+<231::aid-cncr2820671305>3.0.co;2-e. Cancer. 1991. PMID: 1845846 Review.

8

The 52-protein subunit of T4 DNA topoisomerase is homologous to the gyrA-protein of gyrase.

Huang WM. Huang WM. Nucleic Acids Res. 1986 Sep 25;14(18):7379-90. Nucleic Acids Res. 1986. PMID: 3020513 Free PMC article.

9

DNA gyrase: structure and function.

Reece RJ, Maxwell A. Reece RJ, et al. Crit Rev Biochem Mol Biol. 1991;26(3-4):335-75. doi: 10.3109/10409239109114072. Crit Rev Biochem Mol Biol. 1991. PMID: 1657531 Review.

10

Clinical trial of daily low-dose oral etoposide for patients with residual or recurrent cancer of the ovary or uterus.

Yasumizu T, Kato J. Yasumizu T, et al. J Obstet Gynaecol (Tokyo 1995). 1995 Dec;21(6):569-76. doi: 10.1111/j.1447-0756.1995.tb00914.x. J Obstet Gynaecol (Tokyo 1995). 1995. PMID: 8640467 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results